Literature DB >> 10588929

Bepridil differentially inhibits two delayed rectifier K(+) currents, I(Kr) and I(Ks), in guinea-pig ventricular myocytes.

J C Wang1, T Kiyosue, K Kiriyama, M Arita.   

Abstract

1. We investigated the effects of bepridil on the two components of the delayed rectifier K(+) current, i.e., the rapidly activating (I(Kr)) and the slowly activating (I(Ks)) currents using tight-seal whole-cell patch-clamp techniques in guinea-pig ventricular myocytes, under blockade of L-type Ca(2+) current with nitrendipine (5 microM) or D600 (1 microM). 2. Bepridil decreased I(Ks) under blockade of I(Kr) with E4031 (5 microM), in a concentration-dependent manner. The concentration-dependent inhibition of I(Ks) by bepridil was fitted by a curve, assuming one-to-one interactions between the channel and the drug molecule. The concentration of half-maximal inhibition (IC(50)) was found to be 6.2 microM. 3. The effect of bepridil on I(Kr) was assessed using an envelope-of-tails test. In the control condition, a ratio of the tail current to the time-dependent current measured during depolarization was large (>1) at shorter pulses (<200 ms), and it decreased to a steady state value of approximately 0.4 with increases in the pulse duration. Bepridil at a concentration of 2 microM did not decrease this ratio at shorter pulses. 4. In a short-pulse (duration=50 ms) experiment that largely activates I(Kr), the drug was found to block I(Kr) in a cooperative manner (Hill coefficient=3.03) and the IC(50) was 13.2 microM. 5. These results suggest that bepridil at a clinical therapeutic concentration ( approximately 2 microM) selectively blocks I(Ks) but does not inhibit I(Kr). This may relate to the characteristic frequency-dependent effects of bepridil on the action potential duration (APD), e.g., the non-reverse use-dependent prolongation of APD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588929      PMCID: PMC1571802          DOI: 10.1038/sj.bjp.0702959

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Bepridil block of cardiac calcium and sodium channels.

Authors:  A Yatani; A M Brown; A Schwartz
Journal:  J Pharmacol Exp Ther       Date:  1986-04       Impact factor: 4.030

2.  Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibres.

Authors:  D Noble; R W Tsien
Journal:  J Physiol       Date:  1969-01       Impact factor: 5.182

3.  Effects of bepridil, a new antianginal agent, on ambulatory electrocardiography in human volunteers.

Authors:  P Duchêne-Marullaz; J P Kantelip; J F Trolèse
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

4.  Effects of antiarrhythmic drugs on ventricular fibrillation thresholds of normal and ischaemic myocardium in the anaesthetized rat.

Authors:  R J Marshall; A W Muir; E Winslow
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

5.  Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres.

Authors:  F Berger; U Borchard; D Hafner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

6.  Effect of bepridil on intracellular calcium concentration and contraction in cultured rat ventricular myocytes.

Authors:  H Ozaki; H Zaizen; T Kiyosue; M Nasu; M Arita
Journal:  J Cardiovasc Pharmacol       Date:  1999-03       Impact factor: 3.105

7.  Electromechanical effects of bepridil on rabbit isolated hearts.

Authors:  T Anno; T Furuta; M Itoh; I Kodama; J Toyama; K Yamada
Journal:  Br J Pharmacol       Date:  1984-01       Impact factor: 8.739

8.  Effects of verapamil and bepridil on occlusion and reperfusion arrhythmias in the canine heart.

Authors:  A Pelleg; Y Pardo; B Belhassen; B Shargordsky; A Chagnac; S Laniado
Journal:  Cardiology       Date:  1985       Impact factor: 1.869

9.  Effects of bepridil on the electrophysiologic properties of isolated canine and rabbit myocardial fibers.

Authors:  R Kato; B N Singh
Journal:  Am Heart J       Date:  1986-02       Impact factor: 4.749

10.  Stimulation of cardiac myofilament force, ATPase activity and troponin C Ca++ binding by bepridil.

Authors:  R J Solaro; P Bousquet; J D Johnson
Journal:  J Pharmacol Exp Ther       Date:  1986-08       Impact factor: 4.030

View more
  6 in total

1.  Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts.

Authors:  H Nakaya; Y Furusawa; T Ogura; M Tamagawa; H Uemura
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Short- and long-term inhibition of cardiac inward-rectifier potassium channel current by an antiarrhythmic drug bepridil.

Authors:  Fangfang Ma; Hiroki Takanari; Kimiko Masuda; Masaki Morishima; Katsushige Ono
Journal:  Heart Vessels       Date:  2015-10-26       Impact factor: 2.037

3.  Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity.

Authors:  L Kang; M Q Zheng; M Morishima; Y Wang; T Kaku; K Ono
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

4.  Blockade of the forward Na+ /Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+ -mediated cell death.

Authors:  Hui-Jie Hu; Shan-Shan Wang; Yan-Xia Wang; Yan Liu; Xue-Mei Feng; Ying Shen; Liang Zhu; Hong-Zhuan Chen; Mingke Song
Journal:  Br J Pharmacol       Date:  2019-06-17       Impact factor: 8.739

5.  Responsiveness to bepridil predicts atrial substrate in patients with persistent atrial fibrillation.

Authors:  Daisuke Yakabe; Yusuke Fukuyama; Masahiro Araki; Toshihiro Nakamura
Journal:  J Arrhythm       Date:  2021-01-04

6.  Bepridil, a class IV antiarrhythmic agent, can block the TREK-1 potassium channel.

Authors:  Ying Wang; Zhijie Fu; Zhiyong Ma; Na Li; Hong Shang
Journal:  Ann Transl Med       Date:  2021-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.